Tesamorelin vs CJC-1295
Tesamorelin and CJC-1295 are both growth-hormone-releasing hormone (GHRH) analogs studied for their action on pituitary GHRH receptors. Tesamorelin is described in research as a modified GHRH analog engineered for greater stability than the native hormone, and published reviews describe human clinical research on it, particularly on visceral adipose tissue in HIV-associated lipodystrophy. CJC-1295 without DAC, also called modified GRF 1-29, is characterized by a short half-life; without the drug affinity complex its action is brief, which research associates with preserving natural pulsatile growth hormone release. Human data for the no-DAC form are limited, appearing mainly in reviews and anti-doping detection research, while a small randomized trial studied the long-acting DAC form in healthy adults.
Key differences
- 01
Tesamorelin is characterized as a stabilized GHRH analog, whereas CJC-1295 without DAC is characterized by a short half-life and brief action.
- 02
Tesamorelin is at a late-clinical research stage with published human clinical reviews, while CJC-1295 is at an early-clinical stage, with small human studies mostly involving the long-acting DAC form.
- 03
Tesamorelin research has focused on visceral adipose tissue and related metabolic markers, particularly in HIV-associated lipodystrophy, whereas CJC-1295 research has focused on growth hormone release and preservation of its natural pulsatile pattern.
- 04
CJC-1295 also appears in anti-doping analytical detection research and has been identified in seized doping material, a context not described for tesamorelin.
- 05
Research protocols have used 500–2,000 mcg of tesamorelin once daily in 8-week blocks, compared with 100–300 mcg of CJC-1295 five days per week in 12-week blocks, both followed by 4 weeks off.
Side by side
Visceral fat reduction, muscle preservation
GHRH analog — raises GH released per pulse
Late clinical
Early clinical
Performance
Performance
Subcutaneous
Subcutaneous
Research protocols have used 500–2,000 mcg per administration, once daily (pre-sleep), in 8-week blocks with 4 weeks off.
Research protocols have used 100–300 mcg per administration, 5 days per week (pre-sleep), in 12-week blocks with 4 weeks off.
- Visceral adipose tissue in HIV-associated lipodystrophy
- Endogenous GHRH receptor signaling and pituitary action
- Downstream metabolic markers linked to body composition
- Muscle preservation within body-composition research
- Peptide use in sports medicine and musculoskeletal contexts
- Growth hormone release through GHRH receptor signaling
- Preservation of natural pulsatile growth hormone release
- GH and IGF-I secretion in healthy adults (long-acting DAC form)
- Discussion in sports medicine and orthopaedic peptide reviews
- Discussion in healthy-aging peptide reviews
- Analytical detection of GHRH analogs in anti-doping testing
- Adverse event profiles are covered in clinical reviews but are not summarized here
- Human safety data for research-grade material outside clinical trials are limited
- Safety of approved and unapproved peptides in athletic settings has been reviewed as an open question
- Human safety data specific to the no-DAC form are limited
- Adverse events are not summarized in the cited titles
- Reviews discuss safety questions around unapproved peptide therapies
- GHRH synthetic analogs are targeted by anti-doping detection methods and have been identified in seized doping material
5 cited studies
5 cited studies
Studied ranges describe what published research protocols have used. They are not instructions or recommendations. Products are sold for research purposes only; each order ships with a protocol guide for the specific product.
Mechanism
Tesamorelin
Research describes tesamorelin as a modified GHRH analog with greater stability than the native hormone, studied for pituitary action and downstream metabolic signaling.
Stabilized Analog
Studied as a modified releasing-hormone analog engineered for greater stability in research settings.
Body Composition
Explored in research on visceral adipose tissue and associated metabolic markers.
CJC-1295
Research describes it as a GHRH analog acting on pituitary receptors, with the absence of the drug affinity complex keeping its action brief rather than sustained.
GHRH Pathway
Studied as a releasing-hormone analog acting on the pituitary receptors that govern natural hormone pulses.
Short Half-Life
Without DAC its action is brief, which research associates with preserving the body's own pulsatile rhythm.
